Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Revenue (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Revenue data on record, last reported at $581000.0 in Q3 2025.

  • For Q3 2025, Revenue fell 98.82% year-over-year to $581000.0; the TTM value through Sep 2025 reached $31.8 million, down 39.14%, while the annual FY2024 figure was $57.8 million, 67.2% down from the prior year.
  • Revenue reached $581000.0 in Q3 2025 per SGMO's latest filing, down from $18.3 million in the prior quarter.
  • Across five years, Revenue topped out at $158.0 million in Q1 2023 and bottomed at $356000.0 in Q2 2024.
  • Average Revenue over 5 years is $24.9 million, with a median of $18.3 million recorded in 2025.
  • Peak YoY movement for Revenue: plummeted 99.7% in 2024, then soared 5042.13% in 2025.
  • A 5-year view of Revenue shows it stood at $28.6 million in 2021, then decreased by 4.67% to $27.2 million in 2022, then tumbled by 92.5% to $2.0 million in 2023, then surged by 218.32% to $6.5 million in 2024, then plummeted by 91.06% to $581000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $581000.0 in Q3 2025, $18.3 million in Q2 2025, and $6.4 million in Q1 2025.